SCHEMBL1428461

SCHEMBL1428461

Cc1c(C(=O)O)ccn2c(I)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
TDP1 Q9NUW8 1/20 0.38
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
NOTUM Q6P988 2/20 0.35
POLB P06746 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA5A P35218 1/20 0.34
CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23089200 0.80 CCR1 (0.32)
SCHEMBL13035340 0.78 KDM4E (0.47) KDM4EALDH1A1TDP1HSD17B10POLB
SCHEMBL24508317 0.75
SCHEMBL23089765 0.73
SCHEMBL2499260 0.70 KDM4E (0.40) KDM4EALDH1A1GAAPKMTDP1
SCHEMBL22123117 0.69 MEN1 (0.48) ALDH1A1GAAPKMNPC1RAB9A
SCHEMBL12985726 0.68 KDM4E (0.39) KDM4EALDH1A1GAAPKMTDP1
SCHEMBL23104252 0.67
SCHEMBL28093759 0.67 TP53 (0.46) KDM4EALDH1A1GAAHSD17B10NOTUM
SCHEMBL17729459 0.66 MYC (0.41) KDM4EALDH1A1GAAPKMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300465-B1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LTD (GB) 2019-04-17 EP disclosed
US-8796244-B2 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases ASTEX THERAPEUTICS LTD (GB) 2014-08-05 US disclosed
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed
EP-2300465-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES Astex Therapeutics Limited (GB) 2011-03-30 EP disclosed
WO-2009150240-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LIMITED (GB) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ABL1, ERBB2, RET KDM4E 1714/4885ALDH1A1 2527/4885GAA 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.